Milestone Scientific (MLSS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Milestone Scientific stock (MLSS) is currently trading at $0.30. Milestone Scientific PS ratio (Price-to-Sales) is 2.53. Analyst consensus price target for MLSS is $1.00. WallStSmart rates MLSS as Sell.
- MLSS PE ratio analysis and historical PE chart
- MLSS PS ratio (Price-to-Sales) history and trend
- MLSS intrinsic value — DCF, Graham Number, EPV models
- MLSS stock price prediction 2025 2026 2027 2028 2029 2030
- MLSS fair value vs current price
- MLSS insider transactions and insider buying
- Is MLSS undervalued or overvalued?
- Milestone Scientific financial analysis — revenue, earnings, cash flow
- MLSS Piotroski F-Score and Altman Z-Score
- MLSS analyst price target and Smart Rating
Milestone Scientific
📊 No data available
Try selecting a different time range
Smart Analysis
Milestone Scientific (MLSS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Milestone Scientific (MLSS) Key Strengths (0)
Supporting Valuation Data
Milestone Scientific (MLSS) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Revenue declining -6.10%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 7.6x book value
Very low institutional interest at 5.75%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.53x sales
Milestone Scientific (MLSS) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 0 register as strengths (avg 0/10) while 8 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.53), Price/Book (7.60) suggest expensive pricing. Growth concerns include Revenue Growth at -6.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -136.50%, Operating Margin at -48.10%, Profit Margin at -74.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -136.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -6.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MLSS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MLSS's Price-to-Sales ratio of 2.53x trades at a deep discount to its historical average of 12.24x (2th percentile). The current valuation is 94% below its historical high of 45.74x set in Feb 2007, and 18% above its historical low of 2.15x in Dec 2018.
Compare MLSS with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Milestone Scientific (MLSS) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Milestone Scientific is in a turnaround phase, with management focused on restoring profitability. Revenue reached 9M with 6% decline year-over-year. The company is currently unprofitable, posting a -74.7% profit margin.
Key Findings
Generating 75,543 in free cash flow and 81,775 in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 6% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -74.7% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Milestone Scientific.
Bottom Line
Milestone Scientific is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:07:02 AM
About Milestone Scientific(MLSS)
NYSE MKT
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company is headquartered in Livingston, New Jersey.